A5064752432- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- CNS Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Lung Cancer Treatments and Mutations
- Integrated Circuits and Semiconductor Failure Analysis
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- Virus-based gene therapy research
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Peptidase Inhibition and Analysis
- Biomedical Ethics and Regulation
- Cancer Genomics and Diagnostics
- T-cell and Retrovirus Studies
- Acute Myeloid Leukemia Research
- Advancements in Semiconductor Devices and Circuit Design
The University of Texas MD Anderson Cancer Center
2016-2025
Lymphoma Research Foundation
2007-2022
Scripps MD Anderson Cancer Center
2020
The University of Texas Health Science Center at Houston
2015
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2012
National Cancer Institute
2004-2011
Center for Cancer Research
2004-2011
Kurume University
2011
National Institutes of Health
2004-2011
Northwestern University
2009
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of is complex. Natural killer (NK) that have been modified to express an anti-CD19 potential overcome these limitations.
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients 83% 58%, respectively. We report clinical outcomes with axi-cel standard-of-care (SOC) setting indication. PATIENTS AND METHODS Data were collected retrospectively from all LBCL who...
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T therapy, in DLBCL. Patients received low-dose conditioning chemotherapy concurrent cyclophosphamide (500 mg/m2) and fludarabine (30 3 days followed by KTE-C19 at a target dose of 2 × 106 CAR cells/kg. The incidence dose-limiting toxicity (DLT) was primary endpoint. Seven were...
Abstract ZUMA-1 demonstrated a high rate of durable response and manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1), age, disease subtype, stage, International...
We report our experience with 129 cases of double hit lymphoma (DHL), defined as B-cell translocations and/or extra signals involving MYC plus BCL2 BCL6. All were reviewed for histopathological classification. Median age was 62 years (range, 18-85), 84% patients had advanced-stage disease, and 87% an International Prognostic Index score ≥2. Fourteen (11%) a history low-grade follicular lymphoma. translocation present in 81%, 25% patients. IGH-BCL2 12% Two-year event-free survival (EFS) rates...
Vaccination with hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype (Id) conjugated to keyhole limpet hemocyanin (KLH) and administered granulocyte-monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL) -specific immune responses. To determine the clinical benefit of this vaccine, we conducted a double-blind multicenter controlled phase III trial.Treatment-naive patients advanced stage FL achieving complete response (CR) or CR unconfirmed (CRu) after...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric adult a number disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) immune cell-associated neurotoxicity (ICANS), differ markedly from conventional cancer therapeutics. At the time article preparation, US Food Drug Administration (FDA)...